Background: The use of chemotherapeutics during pregnancy is a dilemma for both the patient and the clinician. We report here our 11 years' experience with the use of chemotherapy during pregnancy. Patients: 13 patients undergoing chemotherapy during their current pregnancy were evaluated. The medical data of 5 patients with hematologic malignancies (2 Hodgkin's, 2 non-Hodgkin's lymphoma, and 1 chronic myeloid leukemia), 6 patients with breast cancer, 1 patients with nasopharyngeal cancer, and 1 patient with choriocarcinoma were retrospectively obtained from the ‘perinatal database' of Hacettepe University for the period of January 2002 through March 2016. Results: 4 patients had a medical termination due to teratologic effects. 4 patients had a vaginal delivery, and 5 patients delivered by caesarean section. The 9 newborns who had been exposed to chemotherapeutics were free of congenital anomalies. However, 1 of them died in the early neonatal period due to multi-organ failure (nasopharyngeal cancer). During the 2-year follow-up, we encountered 1 maternal mortality, which was due to multi-organ failure in a non-Hodgkin's lymphoma patient. Conclusion: Physicians must pay attention to potential teratologic problems, and should carefully balance maternal and fetal risks. Selected chemotherapeutic agents can be given in the 2nd and 3rd trimester without any major teratogenic risk. All 9 newborns in our study were free of anomalies, although 1 of them died in the neonatal period.

Journal Section:
Original Article
Keywords:
Pregnancy, Teratology, Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, Chronic myeloid leukemia, Nasopharyngeal cancer, Choriocarcinoma
1.
Turgal M, Beksac K, Basaran D, Yazicioglu A, Ozyuncu O, Aran O, Beksac M: Pregnancy after cancer treatment and pregnancy associated cancer: a single center experience with 96 cases. Gynecology Obstetrics & Reproductive Medicine 2015;21:93-96.
2.
Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V: Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can 2013;35:263-280.
3.
Amant F, Han SN, Gziri MM, Vandenbroucke T, Verheecke M, van Calsteren K: Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015;29:741-753.
4.
Lishner M, Avivi I, Apperley JF, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, van Calsteren K, Vandenbroucke T, van den Heuvel F, Amant F: Hematologic malignancies in pregnancy: management guidelines from an International consensus meeting. J Clin Oncol 2016;34:501-508.
5.
Framarino-Dei-Malatesta M, Perrone G, Giancotti A, Ventriglia F, Derme M, Iannini I, Tibaldi V, Galoppi P, Sammartino P, Cascialli G, Brunelli R: Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature. BMC Cancer 2015;15:951.
6.
Albright CM, Wenstrom KD: Malignancies in pregnancy. Best Pract Res Clin Obstet Gynaecol 2016;33:2-18.
7.
Cardonick E, Iacobucci A: Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-291.
8.
Azim HA Jr, Pavlidis N, Peccatori FA: Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Cancer Treat Rev 2010;36:110-121.
9.
Lavi N, Horowitz NA, Brenner B: An update on the management of hematologic malignancies in pregnancy. Womens Health 2014;10:255-266.
10.
Bachanova V, Connors JM: Hodgkin lymphoma in pregnancy. Curr Hematol Malig Rep 2013;8:211-217.
11.
Gui L, Shi Y, He X, Zhou L, Dong M, Zhou S, Yuan P, Liu P, Yang J, Zhang C, Qin Y, Yang S: (Clinicopathological features and outcomes: analysis of 21 cases of lymphoma in pregnancy). Zhonghua Yi Xue Za Zhi 2015;95:425-429.
12.
Rizack T, Mega A, Legare R, Castillo J: Management of hematological malignancies during pregnancy. Am J Hematol 2009;84:830-841.
13.
Streffer C, Shore R, Konermann G, Meadows A, Uma Devi P, Preston Withers J, Holm LE, Stather J, Mabuchi KHR: Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. Ann ICRP 2003;33:5-206.
14.
Otake M, Schull WJ: Radiation-related brain damage and growth retardation among the prenatally exposed atomic bomb survivors. Int J Radiat Biol 1998;74:159-171.
15.
Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA: Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. JAMA Oncol 2016;2:1065-1069.
16.
Van Calsteren K: Chemotherapy during pregnancy: pharmacokinetics and impact on foetal neurological development. Facts Views Vis Obgyn 2010;2:278-286.
17.
Palani R, Milojkovic D, Apperley JF: Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015;94(suppl 2):S167-176.
18.
Ali R, Ozkalemkas F, Ozcelik T, Ozkocaman V, Ozan U, Kimya Y, Koksal N, Gulten T, Yakut T, Tunali A: Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005;29:971-973.
19.
Yellu M, Pinkard S, Ghose A, Medlin S: CML in pregnancy: a case report using leukapheresis and literature review. Transfus Apher Sci 2015;53:289-292.
20.
Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Ozan U, Kimya Y, Tunali A: Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol 2004;34:215-217.
21.
Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G: A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 2012;33:265-268.
22.
Thauvin-Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas RO, Douvier S, Nivelon-Chevallier A: Exposure to hydroxyurea during pregnancy: a case series. Leukemia 2001;15:1309-1311.
23.
Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA: Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005;23:4192-4197.
24.
Basaran D, Turgal M, Beksac K, Ozyuncu O, Aran O, Beksac MS: Pregnancy-associated breast cancer: clinicopathological characteristics of 20 cases with a focus on identifiable causes of diagnostic delay. Breast Care 2014;9:355-359.
25.
Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A: Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer 2010;46:3158-3168.
26.
Gwyn KM, Theriault RL: Breast cancer during pregnancy. Curr Treat Options Oncol 2000;1:239-243.
27.
Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN: Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999;17:855-861.
28.
Cheng YK, Zhang F, Tang LL, Chen L, Zhou GQ, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Guo Y, Ma J: Pregnancy associated nasopharyngeal carcinoma: a retrospective case-control analysis of maternal survival outcomes. Radiother Oncol 2015;116:125-130.
29.
Lin TI, Lin JC, Ho ES, Chou MM: Nasopharyngeal carcinoma during pregnancy. Taiwan J Obstet Gynecol 2007;46:423-426.
30.
Ganapathi KA, Paczos T, George MD, Goodloe S, Balos LL, Chen F: Incidental finding of placental choriocarcinoma after an uncomplicated term pregnancy: a case report with review of the literature. Int J Gynecol Pathol 2010;29:476-478.
31.
Ghaemmaghami F, Karimi Zarchi M: Early onset of metastatic gestational trophoblastic disease after full-term pregnancy. Int J Biomed Sci 2008;4:74-77.
32.
Bratila E, Ionescu CA, Vladescu CT, Cirstoiu MM, Berceanu C: Gestational choriocarcinoma after term pregnancy: a case report. Rom J Morphol Embryol 2015;56:267-271.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.